Latest Conference Articles

Enriqueta Felip, MD, PhD, discussed the benefits of subcutaneous pembrolizumab for patients with metastatic non–small cell lung cancer.

Sophie Jabban discusses findings from 2 studies that highlight how geographic location, race, ethnicity, and social determinants of health contribute to delays in initiating chemoradiation for patients with cervical cancer.

Stephanie Miller, PhD discusses how artificial intelligence can revolutionize medical research by assisting in drug development and potentially providing more targeted treatments across various diseases.

Tirzepatide-treated patients with chronic kidney disease (CKD), obesity, and heart failure with preserved ejection fraction (HFpEF) had improved renal function both by cystatin C and creatinine.

Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.

Andrew Charles, MD, outlines why calcitonin-gene-related peptide (CGRP) antagonists are increasingly favored as first-line migraine treatments and how pharmacists play a key role in patient education and support.

A study led by Kayla Johnson, PharmD, BCPS, BCPP found that integrating specialty pharmacists into non-multiple sclerosis (MS) neurology clinics led to significantly enhanced patient care and treatment outcomes.

Beth A. Malow, MD, MS, FAAN, said that pharmacists and health care professionals are at the frontlines of collaborating and raising awareness of climate change’s impacts.

Malow also emphasized the importance of staying educated on the potential neurological risks that may occur as a result of climate change.

Nilufer Ertekin-Taner outlines how embracing the biological complexity of neurodegenerative diseases can guide the development of precision therapies akin to those used in oncology.

Nicolas Girard, MD, explains the benefits observed in the MARIPOSA clinical trial among patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated with amivantamab plus lazertinib.

Evolving breast cancer risk models and prevention methods are necessary to improve patient outcomes, according to Sagar Sardesai, MD.

John Ostrominski, MD shares insights into the safety and efficacy of finerenone, based on data from the FINEARTS-HF trial.

Sarah Spinler, PharmD, FCCP, FAHA, FASHP, AACC, discussed management of atrial fibrillation in patients with cancer.

Anna Sophie Mueller, MD discusses how imaging could advance risk identification in cardiovascular care.

Expert shares insights on leadership resilience, emphasizing self-awareness, team development, and maintaining personal worth beyond professional achievements.

Effective management of immune checkpoint inhibitor-related toxicities requires early intervention, evolving guideline adherence, and multidisciplinary collaboration, with steroids remaining a key treatment.

Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions.

Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

The availability of this option could make physicians more comfortable when prescribing ticagrelor, which could help solve the challenge of undertreatment with antiplatelet therapy.

Rivaroxaban offers more predictable dosing, eliminates frequent blood tests, and is less likely to interact with foods.

The results should lead to a guideline update recommending extended treatment with a reduced-dose anticoagulant in this patient population.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.

PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.